Exploring TeraWulf And Two Other High Growth Tech Stocks
In This Article:
The market is up 1.2% over the last week and has risen 30% over the past 12 months, with earnings forecast to grow by 15% annually. In this favorable environment, identifying high-growth tech stocks like TeraWulf can be crucial for investors looking to capitalize on robust market conditions and promising future earnings potential.
Top 10 High Growth Tech Companies In The United States
| Name | Revenue Growth | Earnings Growth | Growth Rating |
|---|---|---|---|
| Super Micro Computer | 20.81% | 27.98% | ★★★★★★ |
| TG Therapeutics | 28.39% | 43.54% | ★★★★★★ |
| Sarepta Therapeutics | 23.58% | 44.12% | ★★★★★★ |
| Invivyd | 42.91% | 70.39% | ★★★★★★ |
| Ardelyx | 27.46% | 66.34% | ★★★★★★ |
| Amicus Therapeutics | 20.32% | 62.37% | ★★★★★★ |
| Clene | 71.89% | 60.05% | ★★★★★★ |
| Travere Therapeutics | 26.68% | 68.80% | ★★★★★★ |
| Seagen | 22.57% | 71.80% | ★★★★★★ |
| ImmunoGen | 26.00% | 45.85% | ★★★★★★ |
Click here to see the full list of 251 stocks from our US High Growth Tech and AI Stocks screener.
Let's uncover some gems from our specialized screener.
TeraWulf
Simply Wall St Growth Rating: ★★★★★☆
Overview: TeraWulf Inc., along with its subsidiaries, operates as a digital asset technology company in the United States and has a market cap of $1.72 billion.
Operations: The company generates revenue primarily through digital currency mining, with a reported revenue of $120.25 million. The market capitalization stands at approximately $1.72 billion.
TeraWulf, amidst a volatile market, is navigating through its unprofitability with strategic maneuvers aimed at robust future growth. With an impressive revenue forecast growing at 53.1% annually, it outpaces the broader US market's 8.7% growth expectation. This surge is underpinned by significant R&D investment, crucial for staying competitive in tech-intensive sectors like AI and high-performance computing. Recent operational highlights include mining 184 bitcoins in August alone while efficiently managing production costs despite challenging economic conditions. Moreover, their proactive financial strategies are evident from the recent auditor change to Deloitte and full repayment of their term loan, positioning them for sustainable expansion and potentially profitable years ahead as forecasted earnings growth hits a remarkable 108.6% annually.
-
Take a closer look at TeraWulf's potential here in our health report.
-
Review our historical performance report to gain insights into TeraWulf's's past performance.
Sarepta Therapeutics
Simply Wall St Growth Rating: ★★★★★★
Overview: Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company specializing in RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for rare diseases, with a market cap of $12.13 billion.